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Summary  
Anaplastic large cell lymphoma (ALCL) is a heterogeneous disease of debateable origin, which in 
children is largely anaplastic lymphoma kinase (ALK) positive with aberrant ALK activity induced 
following the formation of chromosomal translocations. Whilst the survival rates for this disease are 
relatively high, a large proportion of patients suffer disease relapse, in some cases on multiple 
occasions and therefore suffer the toxic side-effects of combination chemotherapy. Traditionally, 
patients are treated with a combination of agents although recent data from relapse patients have 
suggested that low risk patients might benefit from single agent vinblastine and going forward the 
addition of ALK inhibitors to the therapeutic regimen may have beneficial consequences. There are 
also a plethora of other drugs that might be advantageous to patients with ALCL and many of these 
have been identified through laboratory research although the decision as to which drugs to 
implement in trials will not be trivial.  
 
Keywords: Anaplastic Large Cell Lymphoma; Anaplastic Lymphoma Kinase; T cell lymphoma; ALK 
inhibitors  
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Systemic anaplastic large cell lymphoma (ALCL), first described by Stein et al. in 1985, is a 
rare, aggressive CD30-positive non-Hodgkin lymphoma (NHL). A significant proportion of ALCLs are 
associated with the t(2;5)(p23;q35) translocation which was cloned in 1994 by Morris et al., (Morris, 
et al 1994) and following the production of antibodies detecting its gene product - anaplastic 
lymphoma kinase (ALK) (Pulford, et al 1997) our understanding of the mechanisms employed by this 
oncogene has increased considerably. Indeed, in recent times, ALCL has been sub-divided into two 
entities based on aberrant ALK expression as a result of chromosomal translocations giving rise to 
ALCL, ALK+ and ALCL, ALK- sub-classes (Swerdlow, et al 2008) although the majority of children are 
diagnosed with the former. As such, most of the research conducted into mechanisms underlying 
the generation of ALCL have focussed on the role of aberrant ALK activity mostly in the form of the 
t(2;5)(p23;q35) product, Nucleophosmin 1 (NPM)-ALK.  
 
Epidemiology and clinical characteristics 
ALCL accounts for approximately 10 to 15% of all NHL in children and 1-2% of adult NHL. In 
children and adolescents, more than 90% of cases are ALK positive (Brugieres, et al 2009a) compared 
to only 40-50% of adult patients, with a median age of around 30 years in ALCL, ALK+ and 55 in ALK 
negative disease (Sibon, et al 2012).  
Three major entities have been described: primary systemic ALCL, ALK+, primary systemic 
ALCL, ALK- and cutaneous ALCL. More recently, a form of ALCL associated with breast implants has 
been described with these cases being ALK- (Ye, et al 2014) as are most cutaneous ALCL, the latter of 
which are characterised by localised or solitary and often ulcerated skin tumours (Willemze, et al 
2005). Most patients with systemic ALCL present at advanced stages (stages III-IV) with peripheral 
intra-abdominal or mediastinal lymph node involvement frequently associated with B symptoms and 
extra-nodal spread including skin, liver, lung, soft tissue and bone localisation (Brugieres, et al 2009a, 
Sibon, et al 2012). Bone marrow involvement is detected in less than 15% of cases on bone marrow 
biospies and/or smears but, in ALK positive cases, reverse transcription-polymerase chain reaction 
(RT-PCR) for NPM-ALK can detect minimal disease in up to 50% of cases (Mussolin, et al 2005). CNS 
involvment is rare (Williams, et al 2013).  
 
Morphology of ALCL 
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The definition of ALCL has evolved considerably since the first description of strong CD30-
expressing large tumour cells growing within sinuses (Stein, et al 1985). They were defined as 
lymphomas consisting of lymphoid cells that are often large and have abundant cytoplasm and 
pleomorphic, often horseshoe-shaped nuclei. Besides being CD30
+
, most cases also express cytotoxic 
granule-associated proteins and epithelial membrane antigen (EMA). Histologically speaking, ALCLs 
lacking ALK expression are heterogeneous whereas ALCLs expressing ALK were considered relatively 
homogeneous. However, a study of a large series of ALCL positive for ALK protein provided strong 
evidence that they show a broad spectrum of morphologic features ranging from small cell 
neoplasms to an opposite extreme in which very large cells predominate (Benharroch, et al 1998) 
(Figure 1).  
Hence, the 2008 World Health Organisation (WHO) classification recognizes five 
morphological patterns of ALK-positive ALCL sharing the presence of large cells with a highly 
characteristic morphology (eccentric horseshoe- or kidney-shaped nuclei, often with an eosinophilic 
region near the nucleus) referred to as ‘hallmark’ cells (Fig 1): common, small-cell, lymphohistiocytic, 
Hodgkin-like and composite patterns (Swerdlow, et al 2008). An inflammatory background is 
invariably present but its intensity vari s amongst the different morphologic patterns. ALCL, 
common pattern (60%) is composed predominantly of pleomorphic large cells with the hallmark 
features described earlier. The tumour characteristically grows within the sinuses or colonizes the 
paracortex, although complete architectural effacement can also be seen. They often grow in a 
cohesive manner and thus may resemble a metastatic tumor.  
ALCL, lymphohistiocytic pattern (LH-ALCL; 10%) is characterized by tumour cells often 
clustered around blood vessels, admixed with a large number of histiocytes (Pileri, et al 1990). The 
histiocytes typically have finely granular eosinophilic cytoplasm and small, round uniform nuclei and 
are associated with varying numbers of plasma cells. They may mask the malignant cells, which are 
often smaller than in the common pattern, leading to an incorrect diagnosis of a reactive lesion. The 
key to diagnosis is immunohistochemistry using CD30 and ALK-reactive antibodies; this highlights the 
malignant cells scattered among the histiocytes and typically concentrated around blood vessels. 
The ‘small cell pattern’ (SC-ALCL; 5−10%) shows a predominant populaNon of small cells with 
irregular nuclei and abundant clear cytoplasm (Kinney, et al 1993). Hallmark cells are present but are 
difficult to detect among small to medium-sized cells. This variant is often misdiagnosed as 
peripheral T-cell lymphoma not otherwise specified (PTCL, NOS) by conventional examination, but 
the perivascular distribution of hallmark cells can be helpful for diagnosis. Small tumour cells may be 
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only weakly positive or even negative for CD30 (Falini, et al 1999b) and ALK positivity is usually 
restricted to the nucleus of tumour cells.  
The ‘Hodgkin-like pattern’ (HL-ALCL; 3%) is characterised by morphological features 
mimicking nodular sclerosis classical Hodgkin lymphoma, particularly as this latter classification also 
encompasses cases with a composite pattern in which more than one variant can be seen within a 
single lymph node biopsy (Vassallo, et al 2006). CD15 expression is rarely observed but 
aberrant expression of PAX5 can represent a diagnostic challenge in HL-ALCL (Feldman, et al 2010). 
Other less frequently encountered patterns include the monomorphic variant, cases rich in 
multinucleated giant cells or cases with sarcomatoid features. The importance of recognising these 
rare variants lies in the potential for misdiagnosis with serious clinical consequences. By definition, 
malignant cells are strongly positive for CD30 in both the membrane and Golgi and the great 
majority of cases co-express EMA.  
Revisions of the 4th Edtion of the WHO classification have established ALK-negative ALCL as 
a recognised category. Biopsies typically show large pleomorphic cells, sometimes containing 
prominent nucleoli (Fig. 1). In addition, to a variable degree, "hallmark" cells with eccentric, 
horseshoe- or kidney-shaped nuclei are seen. 
 
Phenotype and cell of origin 
ALCL are considered peripheral T-cell lymphomas as they express one or more T-cell 
antigens and are often present at peripheral sites although mediastinal involvement is not 
infrequent (50%) (Lamant, et al 2011). However, due to loss of several pan T-cell antigens, some 
cases may have an apparent ‘null cell’ phenotype, but show evidence of a T-cell lineage at the 
genetic level (see below); CD3 is negative in more than 75% of cases, as are proximal T-cell receptor 
(TCR) signaling proteins (Bonzheim, et al 2004). CD2, CD4 and CD5 are positive in a significant 
proportion of cases (70%) but CD8 is frequently negative. Most cases express cytotoxic associated-
antigens TiA1, granzyme B and perforin.  
It is therefore considered that peripheral cytotoxic T-cells are the cell of origin of this disease 
although recent research calls this into question. Identification of the tumour propagating or cancer 
stem cell for ALCL identified a gene signature characteristic of an early thymic progenitor within this 
distinct cellular subset (Moti, et al 2015). In support of this concept, transcripts for NPM-ALK are 
detectable in 2/103 samples of newborn cord blood sampled from an otherwise healthy population 
(Laurent, et al 2012). Together these data suggest that the generation of the t(2;5) may be an early 
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event occuring in primitive haemopoietic cells and perhaps requiring a thymic environment or at 
least T cell-specific events for transformation although rare ALK+ B cell lymphomas do exist (Laurent, 
et al 2009). In evidence, Malcolm et al. have shown that many ALCLs carry molecular TCR 
rearrangements that would not normally be selected during normal thymic development in that 
2/3rds of tumours examined had major clonal TCRα rearrangements in the absence of a comparable 
major TCRβ rearrangement (Malcolm, et al 2015). Such cells would not normally pass the β-selection 
checkpoint during thymic development instead undergoing apoptosis. These immunogenetic events 
are indicative of aberrant events in the thymi of a majority of patients and in mouse models the 
authors could show that aberrant expression of ALK in the form of the NPM-ALK fusion protein 
allowed thymocytes to bypass β-selection through up-regulation of Notch1 expression. These data 
raise the interesting concept of a thymic origin for this disease whereby ‘primed’ thymocytes 
aberrantly expressing ALK escape into the periphery to eventually develop into tumours (Fig. 2). 
Given that the thymus involutes with increasing age, the predominance of this cancer in children 
also lends support to this theory. 
 
Genetics and Molecular Findings  
As previously mentioned, ALCL are subdivided into ALK+ and ALK- sub-classes with the 
former defined by its genetic features, namely the presence of chromosomal translocations leading 
to expression of ALK fusion proteins. ALK staining may be cytoplasmic, nuclear, and nucleolar or it 
may be restricted to either the cytoplasm or, more rarely, the cell membrane, according to the ALK 
fusion partner. It is important to note that in the small cell pattern and, to a lesser extent, in the 
lymphohistiocytic pattern, ALK staining may be restricted to scattered large cells and hence is easier 
to detect without a nuclear counterstain. Tumours associated with the t(2;5) (75 to 80% of ALK+ 
cases) express NPM-ALK protein and show a characteristic cytoplasmic, nuclear and nucleolar 
staining pattern. This particular pattern can be explained by the formation of two types of dimers 
through oligomerisation domains at the N-terminus of NPM which are retained in the fusion protein. 
The formation of NPM-ALK homodimers mimics ligand binding and leads to activation of the ALK 
catalytic domain. NPM-ALK can also dimerize with wild-type NPM, a protein involved in 
nuclear/cytoplasmic trafficking through its nuclear localisation sequence hence accounting for the 
nuclear localisation of NPM-ALK in tumour cells (Mason, et al 1998). However, variant translocations 
involving ALK and other partner genes on chromosomes 1, 2, 3, 9, 17, 19, and 22 also occur. All 
result in the aberrant expression of ALK, but the distribution of the staining varies, depending on the 
translocation partner.  
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The most frequent variant translocation is the t(1;2)(q25;p23), found in 15% to 18% of ALK+ 
ALCLs (Lamant, et al 1999). In theses cases, which express the TPM3-ALK protein, ALK staining is 
restricted to the cytoplasm of malignant cells and in virtually all cases there is stronger staining on 
the cell membrane. Rare cases of ALCL associated with the t(2,17) (p23,q23) show a unique granular 
cytoplasmic staining pattern. In these cases, the ALK gene is fused to the CLTC gene, which encodes 
the clathrin heavy polypeptide (CLTC) (Touriol, et al 2000). The implication of the clathrin heavy 
polypeptide in the hybrid protein accounts for the granular cytoplasmic staining pattern because the 
CLTC protein is involved in the formation of the clathrin coat on the surface of vesicles. In a single 
report, the moesin (MSN) gene at chromosome Xq11-12 was identified as a new ALK fused gene 
(MSN-ALK fusion protein) in a case of ALCL with a distinct membrane-restricted pattern for ALK 
(Tort, et al 2001). This particular membrane staining pattern for ALK is probably due to the binding 
properties of the N-terminal domain of moesin to cell membrane–associated proteins. In this case, 
the ALK breakpoint was different from that described in all other translocations and occurred within 
the exonic sequence coding for the juxtamembrane portion of ALK. In all other translocations, ALK 
staining is cytoplasmic (TFG-ALK, ATIC-ALK, TPM4-ALK, ALO17-ALK, MYH9-ALK, TRAF1-ALK resulting 
from the t(2;3)(p23;q11), inv(2)(p23q35), t(2;19)(p23;p13), t(2;17)(p23;q25), t(2;22)(p23;q11.2) and 
t(2;9)(p23;q33) respectively) (Cools, et al 2002, Feldman, et al 2013, Lamant, et al 2003, Liang, et al 
2004, Rosenwald, et al 1999, Trinei, et al 2000). Besides the generation of these defining 
translocations, ALCL, ALK+ is relatively stable at the level of the genome with few other karyotypic 
alterations (Salaverria, et al 2008, Youssif, et al 2009).  
In contrast, defining genetic events for ALCL, ALK- have been less forthcoming until recently 
when rearrangements in the DUSP22-IRF4 locus on 6p25 and TP63 were reported, although these 
abnormalities are not specific for ALCL, ALK- (Parrilla Castellar, et al 2014, Vasmatzis, et al 2012). In 
addition, recurrent activating mutations of JAK1 and/or STAT3 genes have been identified in 20% of 
cases (Crescenzo, et al 2015) and miR155 overexpression has been detected (Merkel, et al 2015, 
Merkel, et al 2010). Undoubtedly as techniques develop, more defining (epi)genetic events will be 
described and other studies for example, have identified alterations to the epigenome in ALCL 
inclusive of CpG methylation and expression or down-regulation of small non-coding RNA sequences 
including miRNAs (Ambrogio, et al 2009, Hoareau-Aveilla, et al 2015, Merkel, et al 2015, Merkel, et 
al 2010, Zhang, et al 2011).  
Overall, whilst potentially providing novel therapeutic targets, these findings align ALCL, 
ALK+ and ALCL, ALK- as distinct entities. For example, gene expression studies have shown that a 3-
gene signature (TNFRSF8, BATF, and TMOD1) can distinguish ALCL, ALK- from both ALCL, ALK+ and 
Page 7 of 29 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
8 
 
PTCL, NOS (Agnelli, et al 2012). Hence, these findings could secure ALCL, ALK- as a distinct entity in 
the upcoming revision of the WHO classification and as provisionally proposed in 2008 (Swerdlow, et 
al 2008). 
 
Biological mechanisms implicated in the pathogenesis of ALCL  
Kinase-induced signal transduction 
The large majority of research into the pathogenesis of ALCL has focused on the role of the 
predominant oncogenic event, the generation of the ALK fusion protein NPM-ALK and its 
downstream events. It has been shown exhaustively that NPM-ALK can activate a plethora of signal 
transduction pathways including PI3 Kinase, MAP Kinase and JNK amongst others (Bai, et al 1998, 
Bai, et al 2000, Leventaki, et al 2007, Marzec, et al 2007, Slupianek, et al 2001, Turner and Alexander 
2006, Turner, et al 2007). In addition, STAT3 appears to play a central role in transformation as a 
consequence of its activation in response to aberrant ALK activity in ALCL, ALK+ (Chiarle, et al 2005, 
Zhang, et al 2002) and as a result of mutation events of Jak/STAT proteins in ALCL, ALK- (Crescenzo, 
et al 2015). However, emerging data presented in Varese is unravelling signalling pathways 
downstream of the TCR, a protein complex that is absent in ALCL. It has been known for some time 
that ALCL lack expression of TCR proteins whereby there is a striking absence of TCRβ and CD3 
expression as well as the proximal TCR cell signalling protein Zap-70 (Bonzheim, et al 2004). Until 
recently it remained unknown as to whether this lack of a functional TCR was oncogene-driven or a 
consequence of some other activity or indeed if down-regulation of this signalling axis was necessary 
for cellular transformation. In the interim, epigenetic mechanisms were attributed to silencing by 
CpG methylation of promoter regions of proximal TCR signalling proteins as well as the IL2R 
(Ambrogio, et al 2009, Zhang, et al 2011). The fact that these tumour cells survive and proliferate in 
the absence of transduction via these signalling pathways is perhaps not surprising given that NPM-
ALK can mimic both TCR-induced and IL2R-induced messages (Marzec, et al 2013, Turner, et al 
2007). Whether this is a cause or consequence or indeed if silencing of TCR signalling is essential for 
cellular transformation remains to be determined but new data generated from a combined 
approach to human and murine systems provides some insight. In a murine model of ALCL in which 
all T cells express a TCR specifically recognising ovalbumin peptides as well as NPM-ALK, forced 
signalling through this TCR (via in vivo MHV-ova infection) prevented lymphoid tumour formation 
suggesting that signalling through the TCR in the presence of NPM-ALK is obstructive for tumour 
growth (Malcolm, et al 2015).  However, these data also show that at least transient expression of a 
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TCR is required for thymic emigration and peripheral tumour development in mice (Malcolm, et al 
2015). These data suggest that ALCL tumour cells whilst deriving from the T lineage are in some 
cases unable to functionally act as T cells in the periphery and therefore cannot contribute to an 
inflammatory response, at least not in an antigen-specific manner via the adaptive immune 
response. However, innate T cells have been reported whereby response to signalling through the 
TCR is attenuated allowing cells to act in an innate manner (Wencker, et al 2014). Furthermore, 
some ALCL displayed germline TCR (14%) whilst others resembled γδ T cells at the genetic level 
(Malcolm, et al 2015). Whether such a mechanism applies to ALCL remains to be examined, in 
particular, if a response to antigen contributed to the lymphomagenic process with subsequent 
down-regulation prior to or during transformation in the periphery. Reports of ALCL arising in the 
context of insect bites support this theory to some extent (Lamant, et al 2010). Hence, the timing 
and sequence of events might be of utmost importance to the tumourigenic process (Fig. 2).  
 
Emerging hallmarks and enabling characteristics: Metabolomics 
Whilst many of the ‘traditional’ (hyper)active kinase induced pathways identified in many 
cancers are likewise functional in ALCL, recent research has begun to focus on other facets of 
tumour cells and their microenvironment including the so-called enabling characteristics and 
emerging hallmarks (Chiarle, et al 2008b, Hanahan and Weinberg 2011). In this regard, 
metabolomics has faced a resurgence in cancer research as studies show altered metabolism in 
tumour cells. Indeed, NPM-ALK was shown to induce a shift towards aerobic glycolysis with 
increased lactate and biomass production in a PKM2-dependent manner in tumour cells (McDonnell, 
et al 2013). This is very much an emerging area of research in ALCL and with in-depth analysis of 
proteomics and gene expression datasets will likely provide further insight into the mechanisms of 
ALCL and even future therapeutic targets.  
 
Emerging hallmarks and enabling characteristics: Immune evasion 
Up-regulation of proteins that prevent recognition of tumour cells by the inflammatory 
system is increasingly recognised in a number of cancers and involves expression by the tumour cells 
of a number of proteins including PDL1/PD1 and CTLA-4. Likewise in ALCL, NPM-ALK induces 
expression of PDL1 via STAT3 activity although it remains to be seen whether this has functional 
consequences to the tumour cells (Marzec, et al 2008). More recently, in Varese, the group of 
Megan Lim presented data showing that ALCL lack expression of CD48, a T cell co-stimulatory 
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protein and ligand for the natural killer cell receptor 2B4 (Rolland, et al 2015). Down-regulation of 
CD48 has previously been linked with immune evasion in AML (Elias, et al 2014) and this was also 
demonstrated to be the case for ALK+ ALCL. Given the success and enthusiasm for immunotherapies, 
it is likely that reactivation of the immune system by removing the tumour ‘camouflage’ will be a 
viable therapeutic option for ALCL.  
However, as presented extensively at the meeting, it has been known for some years that 
ALK+ ALCL patients display an immune response to the tumour cells; children produce antibodies to 
ALK and those with a higher titre have a far better prognosis, particularly when combined with an 
absence of detection of minimal disseminated disease (MDD) (Ait-Tahar, et al 2010, Mussolin, et al 
2013, 2015). A cellular response to tumour cells has also been reported in the form of anti-ALK 
specific CD8 and CD4 T cells although of course this is insufficient to completely stem the disease 
(Ait-Tahar, et al 2007, Passoni, et al 2006, Passoni, et al 2002) but efforts continue to be made to 
understand this activity (Woessmann 2015). It is therefore reasonable to speculate that these 
children will also respond well to immunotherapies and ALK vaccination has also been proposed as 
one strategy whereby vaccination of mice with a truncated ALK cDNA has led to CD8 T-cell mediated 
protection against tumour growth (Chiarle, et al 2008a).  
 
Emerging hallmarks and enabling characteristics: Tumour microenvironment 
The tumour microenvironment is essential to tumour growth providing a supportive 
network. It has previously been shown that platelet derived growth factor receptor (PDGFR) and 
PDGFB expression levels are elevated both in transgenic NPM-ALK mouse T cell tumours and primary 
human ALCL tumours as well as patient plasma (Laimer, et al 2012). In NPM-ALK transgenic mice, 
PDGFRB is a direct target of JUNB and cJUN, and serves as a central mediator of tumour progression 
and dissemination. Indeed, previously published data clearly show that inhibition of PDGFR with 
Imatinib induces tumour cell death (in the absence of the other targets of Imatinib activity c-kit and 
Abl) although the mechanism of this activity remains for the most part undetermined (Laimer, et al 
2012). A clinical study for ALK+, PDGFR+ ALCL patients combining brentuximab vedotin and imatinib 
started in Austria in 2015 and is still recruiting. Given that PDGFs and their receptors can drive 
disease progression through cell autonomous effects in cancer cells via autocrine signalling
 
these 
data suggest pleiotropic functions of an autocrine/paracrine loop during ALCL tumour progression 
(Hoch and Soriano 2003). For example, PDGF has been described to have an important impact on the 
surrounding tumour microenvironment and the PDGF/PDGFR axis promotes invasion and metastasis 
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(Raica and Ribatti 2010). Cancers characteristically develop embedded in an environment of non-
malignant connective tissues and closely associate with the so-called ‘tumour stroma’. Reciprocal 
interactions between tumour cells and the stroma have a profound influence on tumour 
development and outcome: It is considered a hallmark of cancer (Hanahan and Weinberg 2011). In 
support of such a role in ALCL, data were presented in Varese showing PDGFR expression on tumour 
or stromal cells in primary patient tissue to be indicative of prognosis and furthermore that deletion 
of PDGFR in tumour cells alone (not stroma) delays but does not inhibit tumour growth as does 
complete ablation of PDGFR (Kenner, et al 2015). Hence, accumulating evidence identifies PDGFRB 
as a central mediator of tumour progression in ALCL cells. While aberrant expression of PDGFRB in 
stromal cells is intriguing, it raises questions as to whether inhibitors of PDGFR are having an effect 
on both the tumour cells and its stroma in ALCL; an additional layer of complexity to the role of 
PDGFR in ALCL which needs to be better explored. 
 
 
Therapeutic strategies  
Front line treatment 
One of the peculiarities of ALCL, ALK+ is its extreme chemo-sensitivity in front line and at 
relapse leading to high response rates with very diverse chemotherapy regimens. Several small 
series of patients were published in the late nineties with very similar event-free survival (EFS) rates 
of about 65-75% despite quite diverse first-line chemotherapy regimens involving a number of 
drugs, with differing cumulative doses and varying durations of treatment (Table 1) (Brugieres, et al 
1998, Laver, et al 2005, Lowe, et al 2009, Rosolen, et al 2005, Seidemann, et al 2001, Williams, et al 
2002).  
Most paediatric groups have now adopted the ALCL99 chemotherapy backbone as the 
reference chemotherapy; given low cumulative doses of agents that are associated with long-term 
side effects such as anthracyclines and alkylating agents in this protocol. This regimen, derived from 
the Berlin-Frankfurt-Munster (BFM)-B NHL protocol, combines a pre-phase and 6 alternating courses 
over a period of 4 months. Long-term toxicity is expected to be very limited but acute toxicity is 
quite significant especially hematologic toxicity with grade 4 neutropenia reported in 60%, mucositis 
in 15% and significant weight gain in 20% of patients (Wrobel, et al 2011). Therapeutic results are 
very similar to those obtained with other regimens: in the ALCL99 trial, the 2 year EFS and overall 
survival (OS) rates were 74% and 92.5% respectively in a large series of more than 350 patients from 
Europe and Japan (Brugieres, et al 2009a).  
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Adult patients are generally treated according to protocols designed for diffuse large-cell 
lymphoma mostly with anthracycline-containing regimens (CHOP, CHOEP (CHOP + etoposide)) or 
ACVBP (Falini, et al 1999a, Gascoyne, et al 1999, Savage, et al 2008, Schmitz, et al 2010, Sibon, et al 
2012, Suzuki, et al 2000). Results are very similar to those obtained in children with a 5-year EFS and 
OS of around 65-80% and 70-90% respectively in ALK positive ALCL (Table 1). ALCL, ALK- are usually 
treated with the same protocols as the ALK+ disease even though the EFS for ALK- patients is poor 
ranging from 15% (Falini, et al 1999a) to 46% (Schmitz, et al 2010). However, the good prognosis of 
ALK positive ALCL seems to be largely related to age of incidence since the prognosis of ALK- and 
ALK+ ALCL is similar in patients less than 40 years (Savage, et al 2008, Schmitz, et al 2010, Sibon, et al 
2012).  
The prognosis of primary cutaneous ALCL is excellent with a treatment based on surgical 
excision or local radiotherapy for localized lesions (Kempf, et al 2011). However, there is still no 
consensus for the treatment of multifocal cutaneous ALCL although the efficacy of Brentuximab 
(Duvic, et al 2015) or vinblastine (Laly, et al 2015) have been reported recently. Multi-agent 
chemotherapy is only recommended for extra-nodal spread beyond local to regional lymph nodes.  
 
Prognostic factors 
Several factors have been shown to be associated with a higher risk of treatment failure in 
children, i.e. clinical factors such as presence of mediastinal disease, visceral (defined as lung, liver, 
or spleen), or cutaneous involvement (Le Deley, et al 2008), high risk histologic subtype defined by 
the presence of a lympho-histiocytic or small cell component (Lamant, et al 2011), positive PCR for 
NPM-ALK in peripheral blood and/or bone marrow at diagnosis (MDD) (Damm-Welk, et al 2007, 
Mussolin, et al 2005), low anti-ALK antibody titres at diagnosis (Ait-Tahar, et al 2010) and detection 
of minimal residual disease (MRD) by PCR for NPM-ALK in the blood after the first course of 
chemotherapy (Damm-Welk, et al 2014). These factors can be employed in the design of future 
treatments in order to stratify patients into risk groups. For example, a combination of MDD and ALK 
antibody titres detected at the time of diagnosis can be used to stratify patients into high (20% of 
patients), intermediate (49% of patients), and low risk groups (31% of patients) with a progression 
free survival (PFS) of 93%, 68% and 28%, respectively as shown in a cohort of 128 patients from the 
BFM and Italian groups, (p < 0.0001) (Mussolin, et al 2013). 
 
Treatment of relapse 
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There is still no gold standard for the treatment of relapse. Several small retrospective 
studies have demonstrated that patients suffering from relapsed ALCL, ALK+ still have a 50-60% 
chance of survival. In these studies various therapeutic approaches including a wide variety of 
chemotherapy regimens and in most publications, autologous or allogeneic hematopoietic stem cell 
transplantation after complete remission (CR) were used (Brugieres, et al 2000, Mori, et al 2006, 
Woessmann, et al 2011). Several prognostic factors, such as a short time to relapse and positive 
immunostaining with an anti-CD3 antibody on tumour specimens at diagnosis, have been shown to 
be associated with a high risk of failure after first relapse (Brugieres, et al 2000, Mori, et al 2006, 
Woessmann, et al 2011). In order to evaluate a risk-adapted strategy, stratified according to the 
time of relapse and immunophenotype, the European Intergroup for Childhood non Hodgkin 
Lymphoma (EICNHL) launched a prospective trial, the ALCL relapse protocol. The final results of the 
ALCL relapse protocol confirmed the good efficacy of allogeneic haematopoietic stem cell 
transplantation in high risk relapse leading to a 3 year EFS after relapse of 64%, whereas the results 
obtained with autologous stem cell transplantation in intermediate risk relapse were quite 
disappointing (3 year EFS of only 41%). In a small cohort of 21 patients with low risk relapse (relapse 
more than one year after diagnosis, CD3 negative), weekly administration of vinblastine proved its 
efficacy with a 3 year EFS of 85% (Ruf, et al 2015). The ability of vinblastine to stimulate a dendritic 
cell response, suggests that the remarkable efficacy of vinblastine monotherapy in patients with 
relapsed/refractory ALCL could be related not only to the cytotoxic effect of vinblastine, but also its 
ability to boost the patient immune response against ALK (Tanaka, et al 2009a, Tanaka, et al 2009b).  
Following the first report demonstrating the efficacy of weekly vinblastine in relapse 
patients (Brugieres, et al 2009b), two different trials, one from the EICHNL group and the second 
from the Children’s Oncology Group (COG), aimed to assess whether adding administration of 
weekly vinblastine to one year of standard chemotherapy would improve EFS of newly diagnosed 
ALCL patients (Alexander, et al 2014, Le Deley, et al 2010). In both trials, this strategy failed to 
reduce the incidence of relapse. However, in the ALCL99 trial, in which the duration of standard 
chemotherapy was only 4 months, the addition of an 8 month maintenance stage with weekly 
vinblastine chemotherapy significantly delayed the occurrence of relapse (13 months versus 6.5 
months in patients without vinblastine) (Le Deley, et al 2010). In the COG trial (Alexander, et al 
2014), in which vinblastine was combined with one year of standard chemotherapy, no benefit from 
the addition of vinblastine was shown. The recent results of the ALCL relapse protocol showing 
durable remission in patients treated with weekly vinblastine for 2 years (Ruf, et al 2015), suggest 
that the duration of vinblastine treatment might need to be increased to 2 years to reduce the risk 
of recurrence after discontinuation of treatment. Given the excellent results obtained with 
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vinblastine in first relapse, the low cost of this drug, its good safety profile compatible with 
outpatient treatment and the absence of known long term side effects, it seems important to test 
whether this drug could substitute multi-agent chemotherapy for front line treatment. This is one of 
the aims of the planned ALCL2 study from the EICNHL group.   
 
New drugs 
Several promising novel agents are being investigated for the treatment of ALCL and may 
lead to profound modifications in therapeutic strategies in the near future. Brentuximab vedotin is 
an anti-CD30 antibody–drug conjugate that selectively delivers an anti-microtubule agent, 
monomethyl auristatin E into CD30-expressing cells. Several phase 2 studies have shown high 
response rates in ALCL. The first reported an overall response rate of 86% and a complete response 
rate of 57% in 58 adult patients with relapsed/refractory ALCL. For the 16 ALCL, ALK+ patients 
included in this trial, overall response and complete remission rates were 81% and 69% respectively, 
in patients who had achieved a complete response; the median duration of response was 13 months 
with either autologous or allogeneic stem cell transplantation after CR, or prolongation of treatment 
with brentuximab vedotin for 12 months (Pro, et al 2012). On the basis of these results, brentuximab 
vedotin was approved in the USA and Europe for the treatment of relapsed ALCL in adults following 
failure of at least one multi-agent chemotherapy protocol. Brentuximab vedotin is given as an 
outpatient treatment at a dose of 1.8mg/kg every 3 weeks and is generally well tolerated. The most 
significant side effect is peripheral neuropathy described in 40% of patients that usually resolves 
within the first few months following the end of treatment. Given this side effect, prolonged 
treatment with brentuximab vedotin may be difficult to manage. Thus, this drug has mostly been 
used as a bridge to transplant in relapsed patients. However, it may also be a feasible option when 
used in combination with multi-agent chemotherapy (Fanale, et al 2014) and is currently being 
tested for front-line treatment in association with cyclophosphamide, doxorubicin, and prednisone 
(CHP) in adults (NCT01777152) and with ALCL99 in children (NCT01979536). Of note, a recent report 
demonstrated that retreatment with brentuximab vedotin is possible and induces a response; a 
complete response rate of 63% was reported in 8 ALCL patients who had previously achieved an 
objective response with prior brentuximab vedotin treatment (Bartlett, et al 2014).  
 
ALK inhibitors are also very promising since ALK tyrosine kinase activity is essential to the 
survival of ALK+ ALCL. Crizotinib, an orally available dual ALK/MET inhibitor, currently approved for 
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advanced ALK-positive non-small cell lung cancer (NSCLC) in adults has been shown to induce high 
response rates: 7/8 ALCL patients achieved CR in a paediatric phase 1 trial (Mosse, et al 2013) and all 
9 patients in a retrospective report of adults treated with crizotinib for refractory/relapsed ALCL 
(Gambacorti Passerini, et al 2014). Crizotinib is given orally and shows a good tolerability profile; the 
most frequent treatment-related adverse effects are transient mild visual disorders and elevated 
amino transferase levels. Unlike in NSCLC in which most patients treated with crizotinib experience 
resistance after a few months, no progressions have been described for ALCL during crizotinib 
treatment so far except for 2 patients with early relapses within 2.5 months of treatment initiation 
(Gambacorti Passerini, et al 2014). Even though it induces CR in most cases, Crizotinib has not yet 
proven curative since it may require life-long treatment; abrupt relapses of ALK+ lymphoma 
following crizotinib discontinuation have been described (Gambacorti Passerini, et al 2015). Most 
patients so far have been treated with crizotinib to induce CR as a bridge to transplant or as a 
prolonged treatment (Gambacorti Passerini, et al 2014, Mosse, et al 2013). Prospective multi-centre 
clinical trials, with strict molecular monitoring will be required to evaluate whether discontinuing 
crizotinib in ALCL is safe and to establish the optimal duration of treatment. Several clinical trials 
testing the efficacy of crizotinib in ALCL patients are on-going including a trial conducted by the COG 
group in which newly diagnosed children and adolescents with ALCL are randomised at diagnosis to 
receive either crizotinib or brentuximab vedotin in combination with multi-agent chemotherapy 
(NCT01979536). The EICNHL group also plans to evaluate whether the addition of crizotinib to multi-
agent chemotherapy is able to improve EFS in high and intermediate risk ALCL. 
There are at least 10 other ALK inhibitors currently at various stages of investigation 
(Katayama, et al 2015). Given the rarity of ALCL and the good response rate obtained with crizotinib, 
only a few of them have been tested in ALCL to date. A CR has been reported in several ALCL 
patients treated with ceritinib, a second generation ALK inhibitor shown to be able to induce CR in 
crizotinib-resistant xenograft models (Richly, et al 2015). Besides ALK inhibitors, several other 
therapeutic options as described above are plausible and include inhibitors of PDGFR, JAK-STAT, 
mTOR, PI3K, immune checkpoint inhibitors and vaccination against ALK (Eyre, et al 2014). The 
availability of such a large number of new therapeutic options should allow for improvements in the 
treatment of ALCL sparing low risk patients from the acute toxicity of multi-agent chemotherapy and 
reducing the failure rate in high risk patients. Given the rarity of this lymphoma, only prospective 
international therapeutic trials including both children and adults with ALCL will allow the evaluation 
of the role of these different therapeutic options in front-line as well as at relapse within a 
reasonable period of time.  
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Conclusions 
It is obvious that we are not short of therapeutic targets for the treatment of ALCL, in 
particular ALK+ ALCL, although given the already high cure rates and relatively small number of 
patients it will be difficult to decide which are the most promising targets to take forward to clinical 
trial. However, the development of robust prognostic markers will assist in stratifying patients in 
order that low risk individuals can be assigned to less toxic treatment arms.  
 
Author Contributions 
All authors wrote the paper, analysed the literature and edited the document. SDT designed the 
review and provided figure 2; LB provided the table; LL provided figure 1.  
 
 
 
  
Page 16 of 29British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
17 
 
References 
 
Agnelli, L., Mereu, E., Pellegrino, E., Limongi, T., Kwee, I., Bergaggio, E., Ponzoni, M., Zamo, A., Iqbal, 
J., Piccaluga, P.P., Neri, A., Chan, W.C., Pileri, S., Bertoni, F., Inghirami, G., Piva, R. & 
European, T.C.L.S.G. (2012) Identification of a 3-gene model as a powerful diagnostic tool for 
the recognition of ALK-negative anaplastic large-cell lymphoma. Blood, 120, 1274-1281. 
Ait-Tahar, K., Barnardo, M.C. & Pulford, K. (2007) CD4 T-helper responses to the anaplastic 
lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. 
Cancer Res, 67, 1898-1901. 
Ait-Tahar, K., Damm-Welk, C., Burkhardt, B., Zimmermann, M., Klapper, W., Reiter, A., Pulford, K. & 
Woessmann, W. (2010) Correlation of the autoantibody response to the ALK oncoantigen in 
pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor 
dissemination and relapse risk. Blood, 115, 3314-3319. 
Alexander, S., Kraveka, J.M., Weitzman, S., Lowe, E., Smith, L., Lynch, J.C., Chang, M., Kinney, M.C., 
Perkins, S.L., Laver, J., Gross, T.G. & Weinstein, H. (2014) Advanced stage anaplastic large cell 
lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of 
APO versus a modified regimen with vinblastine: a report from the children's oncology 
group. Pediatr Blood Cancer, 61, 2236-2242. 
Ambrogio, C., Martinengo, C., Voena, C., Tondat, F., Riera, L., di Celle, P.F., Inghirami, G. & Chiarle, R. 
(2009) NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional 
regulation and epigenetic silencing in lymphoma cells. Cancer Res, 69, 8611-8619. 
Bai, R.Y., Dieter, P., Peschel, C., Morris, S.W. & Duyster, J. (1998) Nucleophosmin-anaplastic 
lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase 
that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol, 18, 6951-
6961. 
Bai, R.Y., Ouyang, T., Miething, C., Morris, S.W., Peschel, C. & Duyster, J. (2000) Nucleophosmin-
anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the 
phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood, 96, 4319-4327. 
Bartlett, N.L., Chen, R., Fanale, M.A., Brice, P., Gopal, A., Smith, S.E., Advani, R., Matous, J.V., 
Ramchandren, R., Rosenblatt, J.D., Huebner, D., Levine, P., Grove, L. & Forero-Torres, A. 
(2014) Retreatment with brentuximab vedotin in patients with CD30-positive hematologic 
malignancies. J Hematol Oncol, 7, 24. 
Benharroch, D., Meguerian-Bedoyan, Z., Lamant, L., Amin, C., Brugieres, L., Terrier-Lacombe, M.J., 
Haralambieva, E., Pulford, K., Pileri, S., Morris, S.W., Mason, D.Y. & Delsol, G. (1998) ALK-
positive lymphoma: a single disease with a broad spectrum of morphology. Blood, 91, 2076-
2084. 
Bonzheim, I., Geissinger, E., Roth, S., Zettl, A., Marx, A., Rosenwald, A., Muller-Hermelink, H.K. & 
Rudiger, T. (2004) Anaplastic large cell lymphomas lack the expression of T-cell receptor 
molecules or molecules of proximal T-cell receptor signaling. Blood, 104, 3358-3360. 
Brugieres, L., Deley, M.C., Pacquement, H., Meguerian-Bedoyan, Z., Terrier-Lacombe, M.J., Robert, 
A., Pondarre, C., Leverger, G., Devalck, C., Rodary, C., Delsol, G. & Hartmann, O. (1998) 
CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two 
consecutive studies of the French Society of Pediatric Oncology. Blood, 92, 3591-3598. 
Brugieres, L., Le Deley, M.C., Rosolen, A., Williams, D., Horibe, K., Wrobel, G., Mann, G., Zsiros, J., 
Uyttebroeck, A., Marky, I., Lamant, L. & Reiter, A. (2009a) Impact of the methotrexate 
administration dose on the need for intrathecal treatment in children and adolescents with 
anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin 
Oncol, 27, 897-903. 
Brugieres, L., Pacquement, H., Le Deley, M.C., Leverger, G., Lutz, P., Paillard, C., Baruchel, A., 
Frappaz, D., Nelken, B., Lamant, L. & Patte, C. (2009b) Single-drug vinblastine as salvage 
Page 17 of 29 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
18 
 
treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the 
French Society of Pediatric Oncology. J Clin Oncol, 27, 5056-5061. 
Brugieres, L., Quartier, P., Le Deley, M.C., Pacquement, H., Perel, Y., Bergeron, C., Schmitt, C., 
Landmann, J., Patte, C., Terrier-Lacombe, M.J., Delsol, G. & Hartmann, O. (2000) Relapses of 
childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a 
report from the French Society of Pediatric Oncology. Ann Oncol, 11, 53-58. 
Chiarle, R., Martinengo, C., Mastini, C., Ambrogio, C., D'Escamard, V., Forni, G. & Inghirami, G. 
(2008a) The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma 
vaccination. Nat Med, 14, 676-680. 
Chiarle, R., Simmons, W.J., Cai, H., Dhall, G., Zamo, A., Raz, R., Karras, J.G., Levy, D.E. & Inghirami, G. 
(2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a possible 
therapeutic target. Nat Med, 11, 623-629. 
Chiarle, R., Voena, C., Ambrogio, C., Piva, R. & Inghirami, G. (2008b) The anaplastic lymphoma kinase 
in the pathogenesis of cancer. Nat Rev Cancer, 8, 11-23. 
Cools, J., Wlodarska, I., Somers, R., Mentens, N., Pedeutour, F., Maes, B., De Wolf-Peeters, C., 
Pauwels, P., Hagemeijer, A. & Marynen, P. (2002) Identification of novel fusion partners of 
ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory 
myofibroblastic tumor. Genes Chromosomes Cancer, 34, 354-362. 
Crescenzo, R., Abate, F., Lasorsa, E., Tabbo, F., Gaudiano, M., Chiesa, N., Di Giacomo, F., 
Spaccarotella, E., Barbarossa, L., Ercole, E., Todaro, M., Boi, M., Acquaviva, A., Ficarra, E., 
Novero, D., Rinaldi, A., Tousseyn, T., Rosenwald, A., Kenner, L., Cerroni, L., Tzankov, A., 
Ponzoni, M., Paulli, M., Weisenburger, D., Chan, W.C., Iqbal, J., Piris, M.A., Zamo, A., 
Ciardullo, C., Rossi, D., Gaidano, G., Pileri, S., Tiacci, E., Falini, B., Shultz, L.D., Mevellec, L., 
Vialard, J.E., Piva, R., Bertoni, F., Rabadan, R., Inghirami, G., European T-Cell Lymphoma 
Study Group, T.C.P.P.C.o.D.i.P.w.P.T.C.L. & the, A.x.C.G.-D.T.M.o.L.M. (2015) Convergent 
mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell 
lymphoma. Cancer Cell, 27, 516-532. 
Damm-Welk, C., Busch, K., Burkhardt, B., Schieferstein, J., Viehmann, S., Oschlies, I., Klapper, W., 
Zimmermann, M., Harbott, J., Reiter, A. & Woessmann, W. (2007) Prognostic significance of 
circulating tumor cells in bone marrow or periph ral blood as detected by qualitative and 
quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood, 110, 
670-677. 
Damm-Welk, C., Mussolin, L., Zimmermann, M., Pillon, M., Klapper, W., Oschlies, I., d'Amore, E.S., 
Reiter, A., Woessmann, W. & Rosolen, A. (2014) Early assessment of minimal residual 
disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell 
lymphoma. Blood, 123, 334-337. 
Duvic, M., Tetzlaff, M.T., Gangar, P., Clos, A.L., Sui, D. & Talpur, R. (2015) Results of a Phase II Trial of 
Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. 
J Clin Oncol, 33, 3759-3765. 
Elias, S., Yamin, R., Golomb, L., Tsukerman, P., Stanietsky-Kaynan, N., Ben-Yehuda, D. & Mandelboim, 
O. (2014) Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood, 123, 
1535-1543. 
Eyre, T.A., Khan, D., Hall, G.W. & Collins, G.P. (2014) Anaplastic lymphoma kinase-positive anaplastic 
large cell lymphoma: current and future perspectives in adult and paediatric disease. Eur J 
Haematol, 93, 455-468. 
Falini, B., Pileri, S., Zinzani, P.L., Carbone, A., Zagonel, V., Wolf-Peeters, C., Verhoef, G., Menestrina, 
F., Todeschini, G., Paulli, M., Lazzarino, M., Giardini, R., Aiello, A., Foss, H.D., Araujo, I., 
Fizzotti, M., Pelicci, P.G., Flenghi, L., Martelli, M.F. & Santucci, A. (1999a) ALK+ lymphoma: 
clinico-pathological findings and outcome. Blood, 93, 2697-2706. 
Page 18 of 29British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
19 
 
Falini, B., Pulford, K., Pucciarini, A., Carbone, A., De Wolf-Peeters, C., Cordell, J., Fizzotti, M., Santucci, 
A., Pelicci, P.G., Pileri, S., Campo, E., Ott, G., Delsol, G. & Mason, D.Y. (1999b) Lymphomas 
expressing ALK fusion protein(s) other than NPM-ALK. Blood, 94, 3509-3515. 
Fanale, M.A., Horwitz, S.M., Forero-Torres, A., Bartlett, N.L., Advani, R.H., Pro, B., Chen, R.W., Davies, 
A., Illidge, T., Huebner, D., Kennedy, D.A. & Shustov, A.R. (2014) Brentuximab vedotin in the 
front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I 
study. J Clin Oncol, 32, 3137-3143. 
Feldman, A.L., Law, M.E., Inwards, D.J., Dogan, A., McClure, R.F. & Macon, W.R. (2010) PAX5-positive 
T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. 
Mod Pathol, 23, 593-602. 
Feldman, A.L., Vasmatzis, G., Asmann, Y.W., Davila, J., Middha, S., Eckloff, B.W., Johnson, S.H., 
Porcher, J.C., Ansell, S.M. & Caride, A. (2013) Novel TRAF1-ALK fusion identified by deep RNA 
sequencing of anaplastic large cell lymphoma. Genes Chromosomes Cancer, 52, 1097-1102. 
Gambacorti Passerini, C., Farina, F., Stasia, A., Redaelli, S., Ceccon, M., Mologni, L., Messa, C., Guerra, 
L., Giudici, G., Sala, E., Mussolin, L., Deeren, D., King, M.H., Steurer, M., Ordemann, R., 
Cohen, A.M., Grube, M., Bernard, L., Chiriano, G., Antolini, L. & Piazza, R. (2014) Crizotinib in 
advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl 
Cancer Inst, 106, djt378. 
Gambacorti Passerini, C., Mussolin, L. & Brugieres, L. (2015) Abrupt relapse of ALK+ lymphoma 
following crizotinib discontinuation. N Engl J Med, in press. 
Gascoyne, R.D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B.F., Greiner, T.C., Morris, S.W., 
Connors, J.M., Vose, J.M., Viswanatha, D.S., Coldman, A. & Weisenburger, D.D. (1999) 
Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults 
with anaplastic large cell lymphoma. Blood, 93, 3913-3921. 
Hanahan, D. & Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674. 
Hoareau-Aveilla, C., Valentin, T., Daugrois, C., Quelen, C., Mitou, G., Quentin, S., Jia, J., Spicuglia, S., 
Ferrier, P., Ceccon, M., Giuriato, S., Gambacorti-Passerini, C., Brousset, P., Lamant, L. & 
Meggetto, F. (2015) Reversal of microRNA-150 silencing disadvantages crizotinib-resistant 
NPM-ALK(+) cell growth. J Clin Invest, 125, 3505-3518. 
Hoch, R.V. & Soriano, P. (2003) Roles of PDGF in animal development. Development, 130, 4769-4784. 
Katayama, R., Lovly, C.M. & Shaw, A.T. (2015) Therapeutic targeting of anaplastic lymphoma kinase 
in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res, 21, 2227-2235. 
Kempf, W., Pfaltz, K., Vermeer, M.H., Cozzio, A., Ortiz-Romero, P.L., Bagot, M., Olsen, E., Kim, Y.H., 
Dummer, R., Pimpinelli, N., Whittaker, S., Hodak, E., Cerroni, L., Berti, E., Horwitz, S., Prince, 
H.M., Guitart, J., Estrach, T., Sanches, J.A., Duvic, M., Ranki, A., Dreno, B., Ostheeren-
Michaelis, S., Knobler, R., Wood, G. & Willemze, R. (2011) EORTC, ISCL, and USCLC consensus 
recommendations for the treatment of primary cutaneous CD30-positive 
lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic 
large-cell lymphoma. Blood, 118, 4024-4035. 
Kenner, L., Kuroll, M., Hartmann, T.N., Krenn, P.W., Schlederer, M., Prutsch, N., Greil, R., Turner, S.D. 
& Merkel, O. (2015) PDGFR blockade as a novel therapy for NPM-ALK+ anaplastic large cell 
lymphoma. Br J Haematol, 171 Suppl 1, 28. 
Kinney, M.C., Collins, R.D., Greer, J.P., Whitlock, J.A., Sioutos, N. & Kadin, M.E. (1993) A small-cell-
predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol, 17, 859-
868. 
Laimer, D., Dolznig, H., Kollmann, K., Vesely, P.W., Schlederer, M., Merkel, O., Schiefer, A.I., Hassler, 
M.R., Heider, S., Amenitsch, L., Thallinger, C., Staber, P.B., Simonitsch-Klupp, I., Artaker, M., 
Lagger, S., Turner, S.D., Pileri, S., Piccaluga, P.P., Valent, P., Messana, K., Landra, I., 
Weichhart, T., Knapp, S., Shehata, M., Todaro, M., Sexl, V., Hofler, G., Piva, R., Medico, E., 
Ruggeri, B.A., Cheng, M., Eferl, R., Egger, G., Penninger, J.M., Jaeger, U., Moriggl, R., 
Page 19 of 29 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
20 
 
Inghirami, G. & Kenner, L. (2012) PDGFR blockade is a rational and effective therapy for 
NPM-ALK-driven lymphomas. Nat Med, 18, 1699-1704. 
Laly, P., Ingen-Housz-Oro, S., Beylot-Barry, M., Verneuil, L., Adamski, H., Brice, P. & Bagot, M. (2015) 
Efficacy of Vinblastine in Primary Cutaneous Anaplastic Large Cell Lymphoma. JAMA 
Dermatol, 151, 1030-1031. 
Lamant, L., Dastugue, N., Pulford, K., Delsol, G. & Mariame, B. (1999) A new fusion gene TPM3-ALK in 
anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood, 93, 3088-
3095. 
Lamant, L., Gascoyne, R.D., Duplantier, M.M., Armstrong, F., Raghab, A., Chhanabhai, M., Rajcan-
Separovic, E., Raghab, J., Delsol, G. & Espinos, E. (2003) Non-muscle myosin heavy chain 
(MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes 
Cancer, 37, 427-432. 
Lamant, L., McCarthy, K., d'Amore, E., Klapper, W., Nakagawa, A., Fraga, M., Maldyk, J., Simonitsch-
Klupp, I., Oschlies, I., Delsol, G., Mauguen, A., Brugieres, L. & Le Deley, M.C. (2011) 
Prognostic impact of morphologic and phenotypic features of childhood ALK-positive 
anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol, 29, 4669-4676. 
Lamant, L., Pileri, S., Sabattini, E., Brugieres, L., Jaffe, E.S. & Delsol, G. (2010) Cutaneous presentation 
of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an 
association in five cases. Haematologica, 95, 449-455. 
Laurent, C., Do, C., Gascoyne, R.D., Lamant, L., Ysebaert, L., Laurent, G., Delsol, G. & Brousset, P. 
(2009) Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare 
clinicopathologic entity with poor prognosis. J Clin Oncol, 27, 4211-4216. 
Laurent, C., Lopez, C., Desjobert, C., Berrebi, A., Damm-Welk, C., Delsol, G., Brousset, P. & Lamant, L. 
(2012) Circulating t(2;5)-positive cells can be detected in cord blood of healthy newborns. 
Leukemia, 26, 188-190. 
Laver, J.H., Kraveka, J.M., Hutchison, R.E., Chang, M., Kepner, J., Schwenn, M., Tarbell, N., Desai, S., 
Weitzman, S., Weinstein, H.J. & Murphy, S.B. (2005) Advanced-stage large-cell lymphoma in 
children and adolescents: results of a randomized trial incorporating intermediate-dose 
methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a 
Pediatric Oncology Group phase III trial. J Clin Oncol, 23, 541-547. 
Le Deley, M.C., Reiter, A., Williams, D., Delsol, G., Oschlies, I., McCarthy, K., Zimmermann, M. & 
Brugieres, L. (2008) Prognostic factors in childhood anaplastic large cell lymphoma: results of 
a large European intergroup study. Blood, 111, 1560-1566. 
Le Deley, M.C., Rosolen, A., Williams, D.M., Horibe, K., Wrobel, G., Attarbaschi, A., Zsiros, J., 
Uyttebroeck, A., Marky, I.M., Lamant, L., Woessmann, W., Pillon, M., Hobson, R., Mauguen, 
A., Reiter, A. & Brugieres, L. (2010) Vinblastine in children and adolescents with high-risk 
anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin 
Oncol, 28, 3987-3993. 
Leventaki, V., Drakos, E., Medeiros, L.J., Lim, M.S., Elenitoba-Johnson, K.S., Claret, F.X. & Rassidakis, 
G.Z. (2007) NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of 
JNK/cJun signaling in anaplastic large-cell lymphoma. Blood, 110, 1621-1630. 
Liang, X., Meech, S.J., Odom, L.F., Bitter, M.A., Ryder, J.W., Hunger, S.P., Lovell, M.A., Meltesen, L., 
Wei, Q., Williams, S.A., Hutchinson, R.N. & McGavran, L. (2004) Assessment of 
t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. 
Am J Clin Pathol, 121, 496-506. 
Lowe, E.J., Sposto, R., Perkins, S.L., Gross, T.G., Finlay, J., Zwick, D. & Abromowitch, M. (2009) 
Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and 
adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer, 52, 
335-339. 
Malcolm, T., Villarese, P., Fairbairn, C., Lamant, L., Trinquand, A., Hook, C.E., Burke, G.A.A., Brugieres, 
L., K., H., Payet, D., Merkel, O., Schiefer, A., Ashankyty, I., Mian, S., Wasik, M., Turner, M., 
Page 20 of 29British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
21 
 
Kenner, L., Asnafi, V., Macintyre, E. & Turner, S.D. (2015) NPM-ALK mimics beta selection 
enabling thymic escape and peripheral lymphoma development. Nature Communications, In 
Press. 
Marzec, M., Halasa, K., Liu, X., Wang, H.Y., Cheng, M., Baldwin, D., Tobias, J.W., Schuster, S.J., 
Woetmann, A., Zhang, Q., Turner, S.D., Odum, N. & Wasik, M.A. (2013) Malignant 
transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK 
recapitulates IL-2-induced cell signaling and gene expression reprogramming. J Immunol, 
191, 6200-6207. 
Marzec, M., Kasprzycka, M., Liu, X., Raghunath, P.N., Wlodarski, P. & Wasik, M.A. (2007) Oncogenic 
tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway 
independently of c-Raf. Oncogene, 26, 813-821. 
Marzec, M., Zhang, Q., Goradia, A., Raghunath, P.N., Liu, X., Paessler, M., Wang, H.Y., Wysocka, M., 
Cheng, M., Ruggeri, B.A. & Wasik, M.A. (2008) Oncogenic kinase NPM/ALK induces through 
STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U 
S A, 105, 20852-20857. 
Mason, D.Y., Pulford, K.A., Bischof, D., Kuefer, M.U., Butler, L.H., Lamant, L., Delsol, G. & Morris, S.W. 
(1998) Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not 
required for malignant transformation. Cancer Res, 58, 1057-1062. 
McDonnell, S.R., Hwang, S.R., Rolland, D., Murga-Zamalloa, C., Basrur, V., Conlon, K.P., Fermin, D., 
Wolfe, T., Raskind, A., Ruan, C., Jiang, J.K., Thomas, C.J., Hogaboam, C.M., Burant, C.F., 
Elenitoba-Johnson, K.S. & Lim, M.S. (2013) Integrated phosphoproteomic and metabolomic 
profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic 
reprogramming in anaplastic large cell lymphoma. Blood, 122, 958-968. 
Merkel, O., Hamacher, F., Griessl, R., Grabner, L., Schiefer, A.I., Prutsch, N., Baer, C., Egger, G., 
Schlederer, M., Krenn, P.W., Hartmann, T.N., Simonitsch-Klupp, I., Plass, C., Staber, P.B., 
Moriggl, R., Turner, S.D., Greil, R. & Kenner, L. (2015) Oncogenic role of miR-155 in anaplastic 
large cell lymphoma lacking the t(2;5) translocation. J Pathol, 236, 445-456. 
Merkel, O., Hamacher, F., Laimer, D., Sifft, E., Trajanoski, Z., Scheideler, M., Egger, G., Hassler, M.R., 
Thallinger, C., Schmatz, A., Turner, S.D., Greil, R. & Kenner, L. (2010) Identification of 
differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and 
ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A, 107, 16228-16233. 
Mori, T., Takimoto, T., Katano, N., Kikuchi, A., Tabuchi, K., Kobayashi, R., Ayukawa, H., Kumagai, 
M.A., Horibe, K. & Tsurusawa, M. (2006) Recurrent childhood anaplastic large cell 
lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol, 132, 594-
597. 
Morris, S.W., Kirstein, M.N., Valentine, M.B., Dittmer, K.G., Shapiro, D.N., Saltman, D.L. & Look, A.T. 
(1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's 
lymphoma. Science, 263, 1281-1284. 
Mosse, Y.P., Lim, M.S., Voss, S.D., Wilner, K., Ruffner, K., Laliberte, J., Rolland, D., Balis, F.M., Maris, 
J.M., Weigel, B.J., Ingle, A.M., Ahern, C., Adamson, P.C. & Blaney, S.M. (2013) Safety and 
activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-
cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol, 14, 
472-480. 
Moti, N., Malcolm, T., Hamoudi, R., Mian, S., Garland, G., Hook, C.E., Burke, G.A., Wasik, M.A., 
Merkel, O., Kenner, L., Laurenti, E., Dick, J.E. & Turner, S.D. (2015) Anaplastic large cell 
lymphoma-propagating cells are detectable by side population analysis and possess an 
expression profile reflective of a primitive origin. Oncogene, 34, 1843-1852. 
Mussolin, L., Damm-Welk, C., Pillon, M., Zimmermann, M., Franceschetto, G., Pulford, K., Reiter, A., 
Rosolen, A. & Woessmann, W. (2013) Use of minimal disseminated disease and immunity to 
NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia, 
27, 416-422. 
Page 21 of 29 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
22 
 
Mussolin, L., Pillon, M., d'Amore, E.S., Santoro, N., Lombardi, A., Fagioli, F., Zanesco, L. & Rosolen, A. 
(2005) Prevalence and clinical implications of bone marrow involvement in pediatric 
anaplastic large cell lymphoma. Leukemia, 19, 1643-1647. 
Parrilla Castellar, E.R., Jaffe, E.S., Said, J.W., Swerdlow, S.H., Ketterling, R.P., Knudson, R.A., Sidhu, 
J.S., Hsi, E.D., Karikehalli, S., Jiang, L., Vasmatzis, G., Gibson, S.E., Ondrejka, S., Nicolae, A., 
Grogg, K.L., Allmer, C., Ristow, K.M., Wilson, W.H., Macon, W.R., Law, M.E., Cerhan, J.R., 
Habermann, T.M., Ansell, S.M., Dogan, A., Maurer, M.J. & Feldman, A.L. (2014) ALK-negative 
anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate 
clinical outcomes. Blood, 124, 1473-1480. 
Passoni, L., Gallo, B., Biganzoli, E., Stefanoni, R., Massimino, M., Di Nicola, M., Gianni, A.M. & 
Gambacorti-Passerini, C. (2006) In vivo T-cell immune response against anaplastic lymphoma 
kinase in patients with anaplastic large cell lymphomas. Haematologica, 91, 48-55. 
Passoni, L., Scardino, A., Bertazzoli, C., Gallo, B., Coluccia, A.M., Lemonnier, F.A., Kosmatopoulos, K. 
& Gambacorti-Passerini, C. (2002) ALK as a novel lymphoma-associated tumor antigen: 
identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood, 99, 2100-2106. 
Pileri, S., Falini, B., Delsol, G., Stein, H., Baglioni, P., Poggi, S., Martelli, M.F., Rivano, M.T., Mason, 
D.Y. & Stansfeld, A.G. (1990) Lymphohistiocytic T-cell lymphoma (anaplastic large cell 
lymphoma CD30+/Ki-1 + with a high content of reactive histiocytes). Histopathology, 16, 
383-391. 
Pro, B., Advani, R., Brice, P., Bartlett, N.L., Rosenblatt, J.D., Illidge, T., Matous, J., Ramchandren, R., 
Fanale, M., Connors, J.M., Yang, Y., Sievers, E.L., Kennedy, D.A. & Shustov, A. (2012) 
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic 
large-cell lymphoma: results of a phase II study. J Clin Oncol, 30, 2190-2196. 
Pulford, K., Lamant, L., Morris, S.W., Butler, L.H., Wood, K.M., Stroud, D., Delsol, G. & Mason, D.Y. 
(1997) Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin 
(NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. 
Blood, 89, 1394-1404. 
Raica, M. & Ribatti, D. (2010) Targeting tumor lymphangiogenesis: an update. Curr Med Chem, 17, 
698-708. 
Richly, H., Kim, T.M., Schuler, M., Kim, D.W., Harrison, S.J., Shaw, A.T., Boral, A.L., Yovine, A. & 
Solomon, B. (2015) Ceritinib in patients with advanced anaplastic lymphoma kinase-
rearranged anaplastic large-cell lymphoma. Blood, 126, 1257-1258. 
Rolland, D., Ivan, E., Elenitoba Johnson, K.S. & Lim, M.S. (2015) ALK+ ALCLs are deficient in the T-cell 
costimulatory protein CD48: role in immune evasion. Br J Haematol, 171 Suppl 1, 21. 
Rosenwald, A., Ott, G., Pulford, K., Katzenberger, T., Kuhl, J., Kalla, J., Ott, M.M., Mason, D.Y. & 
Muller-Hermelink, H.K. (1999) t(1;2)(q21;p23) and t(2;3)(p23;q21): two novel variant 
translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood, 94, 362-364. 
Rosolen, A., Pillon, M., Garaventa, A., Burnelli, R., d'Amore, E.S., Giuliano, M., Comis, M., Cesaro, S., 
Tettoni, K., Moleti, M.L., Tamaro, P., Visintin, G. & Zanesco, L. (2005) Anaplastic large cell 
lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric 
Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer, 104, 2133-2140. 
Ruf, R., Brugieres, L., Pillon, M., Zimmermann, M., Attarbaschi, A., Melgrenn, K., Williams, D., 
Uyttebroeck, A., Wrobel, G., Reiter, A. & Woessman, W. (2015) Risk-adapted Therapy for 
Patients with Relapsed or Refractory ALCL – final report of the Prospective ALCL-Relapse 
Trial of the EICNHL. In: 5th International Symposium on Childhood, Adolescent and Young 
Adult NHL. BJH, Varese. 
Salaverria, I., Bea, S., Lopez-Guillermo, A., Lespinet, V., Pinyol, M., Burkhardt, B., Lamant, L., Zettl, A., 
Horsman, D., Gascoyne, R., Ott, G., Siebert, R., Delsol, G. & Campo, E. (2008) Genomic 
profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative 
anaplastic large cell lymphomas. Br J Haematol, 140, 516-526. 
Page 22 of 29British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
23 
 
Savage, K.J., Harris, N.L., Vose, J.M., Ullrich, F., Jaffe, E.S., Connors, J.M., Rimsza, L., Pileri, S.A., 
Chhanabhai, M., Gascoyne, R.D., Armitage, J.O. & Weisenburger, D.D. (2008) ALK- anaplastic 
large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL 
and peripheral T-cell lymphoma, not otherwise specified: report from the International 
Peripheral T-Cell Lymphoma Project. Blood, 111, 5496-5504. 
Schmitz, N., Trumper, L., Ziepert, M., Nickelsen, M., Ho, A.D., Metzner, B., Peter, N., Loeffler, M., 
Rosenwald, A. & Pfreundschuh, M. (2010) Treatment and prognosis of mature T-cell and NK-
cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the 
German High-Grade Non-Hodgkin Lymphoma Study Group. Blood, 116, 3418-3425. 
Seidemann, K., Tiemann, M., Schrappe, M., Yakisan, E., Simonitsch, I., Janka-Schaub, G., Dorffel, W., 
Zimmermann, M., Mann, G., Gadner, H., Parwaresch, R., Riehm, H. & Reiter, A. (2001) Short-
pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric 
anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-
BFM 90. Blood, 97, 3699-3706. 
Sibon, D., Fournier, M., Briere, J., Lamant, L., Haioun, C., Coiffier, B., Bologna, S., Morel, P., Gabarre, 
J., Hermine, O., Sonet, A., Gisselbrecht, C., Delsol, G., Gaulard, P. & Tilly, H. (2012) Long-term 
outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe 
d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol, 30, 3939-3946. 
Slupianek, A., Nieborowska-Skorska, M., Hoser, G., Morrione, A., Majewski, M., Xue, L., Morris, S.W., 
Wasik, M.A. & Skorski, T. (2001) Role of phosphatidylinositol 3-kinase-Akt pathway in 
nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res, 61, 
2194-2199. 
Stein, H., Mason, D.Y., Gerdes, J., O'Connor, N., Wainscoat, J., Pallesen, G., Gatter, K., Falini, B., 
Delsol, G., Lemke, H. & et al. (1985) The expression of the Hodgkin's disease associated 
antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells 
and histiocytic malignancies are derived from activated lymphoid cells. Blood, 66, 848-858. 
Suzuki, R., Kagami, Y., Takeuchi, K., Kami, M., Okamoto, M., Ichinohasama, R., Mori, N., Kojima, M., 
Yoshino, T., Yamabe, H., Shiota, M., Mori, S., Ogura, M., Hamajima, N., Seto, M., Suchi, T., 
Morishima, Y. & Nakamura, S. (2000) Prognostic significance of CD56 expression for ALK-
positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood, 96, 
2993-3000. 
Swerdlow, S.H., International Agency for Research on Cancer. & World Health Organization. (2008) 
WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency 
for Research on Cancer, Lyon, France. 
Tanaka, H., Matsushima, H., Mizumoto, N. & Takashima, A. (2009a) Classification of 
chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer 
Res, 69, 6978-6986. 
Tanaka, H., Matsushima, H., Nishibu, A., Clausen, B.E. & Takashima, A. (2009b) Dual therapeutic 
efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell 
maturation. Cancer Res, 69, 6987-6994. 
Tort, F., Pinyol, M., Pulford, K., Roncador, G., Hernandez, L., Nayach, I., Kluin-Nelemans, H.C., Kluin, 
P., Touriol, C., Delsol, G., Mason, D. & Campo, E. (2001) Molecular characterization of a new 
ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest, 
81, 419-426. 
Touriol, C., Greenland, C., Lamant, L., Pulford, K., Bernard, F., Rousset, T., Mason, D.Y. & Delsol, G. 
(2000) Further demonstration of the diversity of chromosomal changes involving 2p23 in 
ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain 
polypeptide-like). Blood, 95, 3204-3207. 
Trinei, M., Lanfrancone, L., Campo, E., Pulford, K., Mason, D.Y., Pelicci, P.G. & Falini, B. (2000) A new 
variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive 
anaplastic large cell lymphoma. Cancer Res, 60, 793-798. 
Page 23 of 29 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
24 
 
Turner, S.D. & Alexander, D.R. (2006) Fusion tyrosine kinase mediated signalling pathways in the 
transformation of haematopoietic cells. Leukemia, 20, 572-582. 
Turner, S.D., Yeung, D., Hadfield, K., Cook, S.J. & Alexander, D.R. (2007) The NPM-ALK tyrosine kinase 
mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. 
Cell Signal, 19, 740-747. 
Vasmatzis, G., Johnson, S.H., Knudson, R.A., Ketterling, R.P., Braggio, E., Fonseca, R., Viswanatha, 
D.S., Law, M.E., Kip, N.S., Ozsan, N., Grebe, S.K., Frederick, L.A., Eckloff, B.W., Thompson, 
E.A., Kadin, M.E., Milosevic, D., Porcher, J.C., Asmann, Y.W., Smith, D.I., Kovtun, I.V., Ansell, 
S.M., Dogan, A. & Feldman, A.L. (2012) Genome-wide analysis reveals recurrent structural 
abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood, 
120, 2280-2289. 
Vassallo, J., Lamant, L., Brugieres, L., Gaillard, F., Campo, E., Brousset, P. & Delsol, G. (2006) ALK-
positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin's lymphoma: 
report of 10 cases. Am J Surg Pathol, 30, 223-229. 
Wencker, M., Turchinovich, G., Di Marco Barros, R., Deban, L., Jandke, A., Cope, A. & Hayday, A.C. 
(2014) Innate-like T cells straddle innate and adaptive immunity by altering antigen-receptor 
responsiveness. Nat Immunol, 15, 80-87. 
Willemze, R., Jaffe, E.S., Burg, G., Cerroni, L., Berti, E., Swerdlow, S.H., Ralfkiaer, E., Chimenti, S., Diaz-
Perez, J.L., Duncan, L.M., Grange, F., Harris, N.L., Kempf, W., Kerl, H., Kurrer, M., Knobler, R., 
Pimpinelli, N., Sander, C., Santucci, M., Sterry, W., Vermeer, M.H., Wechsler, J., Whittaker, S. 
& Meijer, C.J. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood, 105, 3768-
3785. 
Williams, D., Mori, T., Reiter, A., Woessman, W., Rosolen, A., Wrobel, G., Zsiros, J., Uyttebroeck, A., 
Marky, I., Le Deley, M.C. & Brugieres, L. (2013) Central nervous system involvement in 
anaplastic large cell lymphoma in childhood: results from a multicentre European and 
Japanese study. Pediatr Blood Cancer, 60, E118-121. 
Williams, D.M., Hobson, R., Imeson, J., Gerrard, M., McCarthy, K. & Pinkerton, C.R. (2002) Anaplastic 
large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom 
Children's Cancer Study Group chemotherapy regimens. Br J Haematol, 117, 812-820. 
Woessmann, W. (2015) Immune response to ALK in ALK-positive anaplastic large cell lymphoma. Br J 
Haematol, 171 Suppl 1, 23-24. 
Woessmann, W., Zimmermann, M., Lenhard, M., Burkhardt, B., Rossig, C., Kremens, B., Lang, P., 
Attarbaschi, A., Mann, G., Oschlies, I., Klapper, W. & Reiter, A. (2011) Relapsed or refractory 
anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster 
(BFM)-type first-line therapy: a BFM-group study. J Clin Oncol, 29, 3065-3071. 
Wrobel, G., Mauguen, A., Rosolen, A., Reiter, A., Williams, D., Horibe, K., Brugieres, L. & Le Deley, 
M.C. (2011) Safety assessment of intensive induction therapy in childhood anaplastic large 
cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer, 56, 1071-1077. 
Ye, X., Shokrollahi, K., Rozen, W.M., Conyers, R., Wright, P., Kenner, L., Turner, S.D. & Whitaker, I.S. 
(2014) Anaplastic large cell lymphoma (ALCL) and breast implants: breaking down the 
evidence. Mutat Res Rev Mutat Res, 762, 123-132. 
Youssif, C., Goldenbogen, J., Hamoudi, R., Carreras, J., Viskaduraki, M., Cui, Y.X., Bacon, C.M., Burke, 
G.A. & Turner, S.D. (2009) Genomic profiling of pediatric ALK-positive anaplastic large cell 
lymphoma: a Children's Cancer and Leukaemia Group Study. Genes Chromosomes Cancer, 
48, 1018-1026. 
Zhang, Q., Raghunath, P.N., Xue, L., Majewski, M., Carpentieri, D.F., Odum, N., Morris, S., Skorski, T. 
& Wasik, M.A. (2002) Multilevel dysregulation of STAT3 activation in anaplastic lymphoma 
kinase-positive T/null-cell lymphoma. J Immunol, 168, 466-474. 
Zhang, Q., Wang, H.Y., Liu, X., Bhutani, G., Kantekure, K. & Wasik, M. (2011) IL-2R common gamma-
chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) 
Page 24 of 29British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
25 
 
and acts as a tumor suppressor by targeting NPM-ALK. Proc Natl Acad Sci U S A, 108, 11977-
11982. 
 
  
Page 25 of 29 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
26 
 
Table 1: The outcome of various chemotherapy strategies applied to the treatment of ALCL, ALK+ 
patients. 
Reference Strategy 
♯of 
patients 
EFS OS 
Children and adolescents 
(Brugieres, et al 
1998) 
B cell strategy (COPADM (cyclophosphamide, 
vincristine, prednisone, doxorubicin, dexamethasone, 
methotrexate) + Maintenance) 
82 66% 83% 
(Seidemann, et 
al 2001) 
B cell regimen (BFM-B) 89 76% ND 
(Williams, et al 
2002) 
B Cell regimen (LMB) 72 59% 65% 
(Rosolen, et al 
2005) 
T Cell regimen 34 68% 85% 
(Laver, et al 
2005) 
APO (doxorubicin, prednisone, vincristine) 
+randomization of HDMTX and high dose (HD) AraC 
86 72% 88% 
(Lowe, et al 
2009) 
Compressed T-cell regimen 86 68% 80% 
(Brugieres, et al 
2009a) 
B-cell regimen + randomization of vinblastine 352 73% 92% 
(Alexander, et 
al 2014) 
APO + randomization of vinblastine 125 74% 84% 
Adults 
(Falini, et al 
1999a) 
Various doxorubicin containing regimens 53 82% 71% 
(Gascoyne, et al 
1999) 
Various doxorubicin containing regimens 31 82% 93% 
(Suzuki, et al 
2000) 
Various doxorubicin containing regimens 83 ND 72% 
(Savage, et al 
2008) 
Various doxorubicin containing regimens 87 60% 70% 
(Schmitz, et al 
2010) 
6 to 8 courses of CHO(E)P (cyclophosphamide, 
doxorubicin, vincristine, etoposide, prednisone) 
78 76% 87% 
(Sibon, et al 
2012) 
ACVPB  (doxorubicin, cyclophosphamide, vinblastine, 
prednisone, bleomycin) or CHOP 
64 72% 82% 
 
EFS, event free survival; OS, overall survival; ND = not determined. 
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Figure Legends 
Figure 1: Morphological variants of ALCL A. Common type ALCL consists only of large-sized cells 
(arrow: hallmark cell) (H&E). B-C. Malignant cells are often masked by reactive histiocytes in 
Lympho-Histiocytic ALCL (H&E) (arrow: hallmark cell) and highlighted by ALK1 antibody staining. D-E. 
In the Small Cell variant, hallmark cells (arrow) are scattered among a predominant population of 
small-sized neoplastic cells positive for ALK1 staining. F. In ALK-negative ALCL, tumour cells are often 
more pleomorphic (H&E). G. ALK-negative ALCL may share a typical perivascular distribution of 
CD30-positive neoplastic cells as seen with ALK-positive ALCL 
 
Figure 2: A thymic origin for ALCL. In this model, the t(2;5) or variant translocation occurs in 
haemopoietic stem cells or thymic progenitors whereby NPM-ALK is permissive of cellular survival in 
the thymus despite aberrant TCR rearrangements. These ‘primed’ cells may go undetected until a 
secondary event(s) occurs that leads to clonal expansion and tumour development. This event may 
be induced as a consequence of an inflammatory response as evidenced by ALCL in the context of 
insect bites but might also be initiated in an innate manner. ETP = early thymic progenitor, DN = 
double negative thymocyte, DP = double positive thymocyte, SP = single positive. 
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